

Children's Hospital Medical Center, Cincinnati, OH, USA; ¹⁵Hospital Santa Maria, Lisbon, Portugal; ¹⁶CHRU de Lille, Lille, France; ¹⁷BridgeBio Pharma, San Francisco, CA, USA; ¹⁸Erasmus MC, Rotterdam, Netherlands; ¹⁹Royal North Shore Hospital, Sydney, Australia; ²⁰Aarhus University Hospital, Aarhus N, Denmark

Disclosure: **S.W. Ing:** Advisory Board Member; Self; Ultragenyx, Amolyt. Grant Recipient; Self; Alexion Pharmaceuticals, Inc.. Research Investigator; Self; BridgeBio Pharma, Takeda, Amolyt, Radius Health, Inc, Ultragenyx. **P. Harmatz:** Research Investigator; Self; BridgeBio Pharma. **S. Mora:** Research Investigator; Self; BridgeBio Pharma. **E.A. Imel:** Research Investigator; Self; BridgeBio Pharma. **P.J. Tebben:** Research Investigator; Self; BridgeBio Pharma. **M.L. Warren:** Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt. Speaker; Self; Ascendis. **N. Ma:** Research Investigator; Self; Calcilytix Therapeutics, Ultragenyx, Inozyme. Other; Self; Up To Date. **A.A. Khan:** Research Investigator; Self; BridgeBio Pharma, Ascendis. **A. Palermo:** Research Investigator; Self; BridgeBio Pharma. **B. Decallonne:** Research Investigator; Self; BridgeBio Pharma. **S. Lemoine:** Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. **G. Mantovani:** Research Investigator; Self; BridgeBio Pharma. **A. Linglart:** Consulting Fee; Self; Alexion, Novo Nordisk, Merck, Pfizer, Inc.. Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. **H. Wasserman:** Research Investigator; Self; BridgeBio Pharma. **A.P. Barbosa:** Research Investigator; Self; BridgeBio Pharma. **C. Cardot-bauters:** Research Investigator; Self; BridgeBio Pharma. **M. Roberts:** Employee; Self; BridgeBio Pharma. **A. Mathew:** Employee; Self; BridgeBio Pharma. **S. Adler:** Employee; Self; BridgeBio Pharma. **M.C. Zillikens:** Research Investigator; Self; BridgeBio Pharma. **R.J. Clifton-Bligh:** Consulting Fee; Self; Ipsen, Kyowa Kirin, Amgen Inc, Eisai. Research Investigator; Self; BridgeBio Pharma. **L. Rejnmark:** Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt, Takeda, Kyowa Kirin.

Abstract citation ID: bvae163.383

Bone And Mineral Metabolism 9295

Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study

Steven Wai Ing, MD, MSCE¹, Paul Harmatz, MD², Stefano Mora, MD³, Erik Allen Imel, MD⁴, Peter J. Tebben, MD⁵, Mark Lowe Warren, MD⁶, Nina Ma, MD⁷, Aliya Aziz Khan, MD, FRCP, FACP, FACE⁸, Andrea Palermo, MD, PhD⁹, Brigitte Decallonne, MD, PhD¹⁰, Sandrine Lemoine¹¹, Giovanna Mantovani, MD, PhD¹², Agnes Linglart, MD, PhD¹³, Halley Wasserman, MD¹⁴, Ana Paula Barbosa, MD, PhD¹⁵, Catherine Cardot-Bauters¹⁶, Mary Scott Roberts, MD¹⁷, Arun Mathew, PharmD, MBA, MPS, MPH¹⁷, Scott Adler, MD¹⁷, Maria Carola Zillikens, MD, PhD¹⁸, Roderick John Clifton-Bligh, MBBS, PhD, FRACP¹⁹, and Lars Rejnmark, MD, PhD, DMSc²⁰

¹Ohio State University Wexner Medical Center, Columbus, OH, USA; ²UCSF Benioff Children's Hospital, San Francisco, CA, USA; ³IRCCS Ospedale San Raffaele, Milano, Italy; ⁴Indiana University School of Medicine, Indianapolis, IN, USA; ⁵Mayo Clinic Rochester, Rochester, MN, USA; ⁶PHYSICIANS EAST, Greenville, NC, USA; ⁷BridgeBio Pharma, Aurora, CO, USA; ⁸McMaster University, Oakville, ON, Canada; ⁹Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; ¹⁰University Hospitals Leuven, Leuven, Belgium; ¹¹HCL Hospital Edouard Herriot and University of Lyon, Lyon, France; ¹²University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹³AP-HP HOPITAL BICETRE, Le Kremlin Bicetre, France; ¹⁴Cincinnati

Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (*CASR*) variants, is characterized by low parathyroid hormone (PTH) concentrations, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. While a rare disease, ADH1 is one of the more frequently identified causes of genetic hypoparathyroidism. Conventional therapy includes calcium (Ca) and/or active vitamin D, but this regimen incompletely corrects the hypocalcemia and is associated with persistent hypercalciuria, which may result in renal complications including nephrocalcinosis (NC), nephrolithiasis (NL), and chronic kidney disease (CKD). The CLARIFY disease monitoring study [NCT05227287] is a global, multicenter, longitudinal study to understand disease burden, management, and progression in children and adults with ADH1 over a 5-year period. Here we report data on the characteristics of adult participants at study entry. As of November 2023, 45 adults (≥ 18 years) with ADH1 were enrolled, with a mean \pm SD age of 42.1 \pm 16.5 years (range 18-80). The mean \pm SD age of a hypocalcemia diagnosis was 19.1 \pm 19.1 years, while the mean \pm SD age for a diagnosis of ADH1 was 28.2 \pm 20.6 years. As

reported on medical history, in decreasing order of prevalence, 36% (16) had NC, 22% (10) had intracranial calcifications, 11% (5) had history of seizures, 11% (5) had CKD, 9% (4) had cataracts, 7% (3) had NL, and 4% (2) had undergone renal transplant. Treatment data were available for 43 participants and included the following: 74% (32) Ca and active vitamin D, 9% (4) Ca alone, 9% (4) active vitamin D alone, 37% (16) magnesium, 33% (14) thiazide diuretics, 26% (11) potassium, 7% (3) phosphate binder, 7% (3) PTH, and 5% (2) no treatment. Mean \pm SD fasting values collected prior to conventional therapy dose are presented. PTH concentrations (10.1 \pm 8.2 pg/mL [nl 15-65]) and albumin-corrected calcium ([cCa]=7.5 \pm 1.0 mg/dL [nl 8.5-10.5]) were low. Despite the low mean cCa, the mean 24-hr urine calcium was elevated (268 \pm 183 mg/d, [nl <250 women, <300 men]). Blood phosphate was 4.8 \pm 0.8 mg/dL [nl 2.5-4.8] while blood magnesium was 1.8 \pm 0.2 mg/dL [nl 1.8-2.4]. 25-OH vitamin D was 35.0 \pm 13.5 ng/mL [nl 30-80]. Renal function as assessed by CKD-EPI_{Cr}_R showed eGFR of 86 \pm 23 mL/min/1.73m² (range 36-123). This study represents the largest cohort of adults with ADH1 described to date. These data highlight variability in therapeutic approaches in a real-world setting with some participants receiving up to 6 different medications/supplements. Despite being followed in expert centers, and treated with available therapies, patients on average have low cCa with relatively high 24-hr urine calcium excretion. The CLARIFY study provides an opportunity to better understand the progression and burden of disease in participants with ADH1.

Presentation: 6/3/2024